問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Chang Gung Medical Foundation Chang Gung Memorial Hospital, Keelung

Recruiting

List

63Cases

2025-06-02 - 2029-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2020-12-01 - 2025-12-31

Phase IV

Active
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan Population

  • Condition/Disease

    Lupus Nephritis

  • Test Drug

    Myfortic 180 mg、360 mg Gastro-Resistant Tablets

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2020-06-15 - 2026-12-31

Phase III

Active
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease

  • Condition/Disease

    CVD

  • Test Drug

    TQJ230

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting10Sites

2020-04-01 - 2022-05-31

Phase II

Completed
Randomized, double-blind, parallel group, Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory and/or unexplained chronic cough (RUCC)

  • Condition/Disease

    refractory and/or unexplained chronic cough (RUCC)

  • Test Drug

    BAY 1817080

Participate Sites
5Sites

Recruiting5Sites

2023-01-16 - 2025-08-30

Phase III

Active
A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA

  • Condition/Disease

    Prevention of Ischemic Stroke

  • Test Drug

    asundexianPlacebo

Participate Sites
23Sites

Not yet recruiting6Sites

Recruiting17Sites

2021-04-01 - 2024-12-18

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting1Sites

Recruiting10Sites

2022-01-01 - 2026-03-31

Phase II

Active
A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    CVM-1118 膠囊 (又名 CVM-1118 速放膠囊 )

Participate Sites
6Sites

Recruiting6Sites

2020-06-01 - 2027-12-31

Phase I/II

Active
Phase 1B Trial of ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

  • Condition/Disease

    Newly Diagnosed Glioblastoma Multiforme (GBM)

  • Test Drug

    ADI-PEG 20

Participate Sites
6Sites

Recruiting6Sites

2023-02-01 - 2028-01-31

Phase II

Active
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of ADI-PEG 20 or Placebo in Subjects With Nonalcoholic Steatohepatitis (NASH)

  • Condition/Disease

    Nonalcoholic Steatohepatitis (NASH)

  • Test Drug

    ADI-PEG 20

Participate Sites
10Sites

Not yet recruiting6Sites

Recruiting4Sites

2019-04-08 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

1 2 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB